Patent ID: 8497251

Claim:
A pharmaceutical composition for treating latent HIV infection, comprising: (1) an effective amount of an anti-IκBα agent, an anti-IκBε agent or both; and (2) a pharmaceutically acceptable carrier, wherein said anti-human IκBα agent and/or said anti-human IκBε agent are selected from the group consisting of iRNA agents, antisense RNA, vectors expressing iRNA agents and/or antisense RNA, PNA, anti-IκBα antibodies, anti-IκBε antibodies, and small molecules that target IκBα-NFκB and IκBε-NFκB interactions, wherein said anti-human IκBα agent or said anti-human IκBε agent reduces the level of IκBα or IκBε gene expression or a biological activity of the IκBα or IκB-ε protein in cells latently infected by HIV, resulting in activation of HIV expression in such cells.